samdt3144-119
Amendment to: Appropriations Act, 2026
Why China-relevant: prevent the importation of GLP-1 and GIP/GLP-1 drugs that appear to be counterfeit, unapproved, misbranded, or adulterated from the Republic of China or other foreign countries, including any bulk drug substance or active pharmaceutical ingredient from facilities in China.
Timeline
- Filed
- Passed chamber (vote) [house]vehicle
- Passed chamber (vote) [senate]vehicle
Vehicle: Appropriations Act, 2026
- Introduced
- Passed committee
- Passed House
- Passed Senate
- Sent to President next step
- Became law
done next step still ahead
Signals — secondary, directional
Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.
Shares that might be influenced
Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.
Targeted import enforcement can affect China-linked API and drug supply channels.
| Ticker | Name (Local) | Name (EN) | Restriction Lists |
|---|---|---|---|
| 688235.SS | 百济神州 | BEONE MEDICINES | |
| 600276.SS | 恒瑞医药 | HENGRUI PHARMA | |
| 603259.SS | 药明康德 | WuXi AppTec | |
| 3692.HK | 翰森制药 | Hansoh Pharmaceutical Group Company Limited | |
| 300760.SZ | 迈瑞医疗 | MR | |
| 2269.HK | 药明生物 | WUXI BIOLOGICS (CAYMAN) INC. | |
| 1801.HK | 信达生物 | Innovent Biologics, Inc. | |
| 6618.HK | 京东健康 | JD Health International Inc. | |
| 6990.HK | 科伦博泰生物 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | |
| 9926.HK | 康方生物 | Akeso,Inc. |